AGEN Share Price

Open 4.57 Change Price %
High 4.62 1 Day 0.03 0.67
Low 4.49 1 Week 0.07 1.57
Close 4.54 1 Month 0.77 20.42
Volume 1434188 1 Year 1.54 51.33
52 Week High 7.49
52 Week Low 2.65
AGEN Important Levels
Resistance 2 4.66
Resistance 1 4.61
Pivot 4.55
Support 1 4.47
Support 2 4.42
NASDAQ USA Most Active Stocks
SCHN 26.75 0.38%
SCHN 26.75 0.38%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
DCTH 0.17 6.25%
More..
NASDAQ USA Top Gainers Stocks
LLEN 0.02 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
GALT 1.94 31.97%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEHR 4.99 21.41%
BGMD 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Agenus Inc. (NASDAQ: AGEN)

AGEN Technical Analysis 2
As on 21st Feb 2017 AGEN Share Price closed @ 4.54 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4.78 & Strong Buy for SHORT-TERM with Stoploss of 4.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
AGEN Target for February
1st Target up-side 4.42
2nd Target up-side 4.71
3rd Target up-side 5.01
1st Target down-side 3.58
2nd Target down-side 3.29
3rd Target down-side 2.99
AGEN Other Details
Segment EQ
Market Capital 112052832.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.antigenics.com
AGEN Address
AGEN
3 Forbes Road
Lexington, MA 02421
United States
Phone: 781-674-4400
Fax: 781-674-4200
AGEN Latest News
Buy, Sell or Hold? Analysts Approach: Agenus Inc. (AGEN), Varian Medical ...   The USA Commerce   - 21st Feb 17
Agenus Inc. (AGEN) Soars 6.62% on February 20   Equities.com   - 21st Feb 17
Agenus Inc Risk Points versus Health Care   CML News   - 20th Feb 17
Agenus Inc. (AGEN) Soars 6.62% on February 17   Equities.com   - 18th Feb 17
Agenus Inc. (AGEN) Moves Higher on Volume Spike for February 17   Equities.com   - 18th Feb 17
Agenus Inc. (AGEN) Plunges 5.37% on February 16   Equities.com   - 17th Feb 17
Agenus Inc. (AGEN) Moves Higher on Volume Spike for February 15   Equities.com   - 16th Feb 17
AGENUS INC.   StreetInsider.com   - 14th Feb 17
Why Agenus Inc. Stock Plummeted 44.7% in October   Motley Fool   - 07th Nov 16
Why Fret Over Agenus Inc. Q3 Results?   Motley Fool   - 27th Oct 16
Interactive Technical Analysis Chart Agenus Inc. ( AGEN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Agenus Inc.
AGEN Business Profile
Agenus Inc., including its subsidiaries, (Agenus) is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases. The Company's core technology portfolio consists of its Saponin Platform (based on its saponin adjuvant based technologies) and its Heat Shock Protein (HSP) Platform (based on its HSP based technologies). The Company's key candidates from these technology platforms include QS-21 Stimulon adjuvant (QS-21), the Prophage Series vaccines and HerpV. The Company's products and technologies under development include QS-21. A number of pharmaceutical and biotechnology companies have licensed QS-21 from the Company for use in vaccines to treat a wide variety of human diseases. The Company has retained worldwide manufacturing rights for QS-21. It has the right to subcontract manufacturing for QS-21 and it has a supply agreement with a contract manufacturer for the production of QS-21 through September 2012. The Prophage Series vaccines describe its portfolio of patient-specific HSP-based therapeutic cancer vaccines, including the R-Series candidates in renal cell carcinoma (RCC), M-Series candidates in melanoma, and G-Series candidates in glioma.